EP1874354A1 - Nutrient composition comprising green tea polyphenols for treating osteosarcoma - Google Patents

Nutrient composition comprising green tea polyphenols for treating osteosarcoma

Info

Publication number
EP1874354A1
EP1874354A1 EP05738146A EP05738146A EP1874354A1 EP 1874354 A1 EP1874354 A1 EP 1874354A1 EP 05738146 A EP05738146 A EP 05738146A EP 05738146 A EP05738146 A EP 05738146A EP 1874354 A1 EP1874354 A1 EP 1874354A1
Authority
EP
European Patent Office
Prior art keywords
compound
composition
osteosarcoma
ascorbate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05738146A
Other languages
German (de)
French (fr)
Inventor
M. Waheed Roomi
Vadim Ivanov
Tatiana Kalinovsky
Aleksandra Niedzwiecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1874354A1 publication Critical patent/EP1874354A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Definitions

  • the present invention relates to the use of a composition comprising an ascorbic acid compound, a L-lysine compound, a L-proline compound, and a polyphenol compound for the preparation of a pharmaceutical composition for treating osteosarcoma. Moreover, the invention further relates to a method of treatment wherein said composition is administered to a subject suffering from osteosarcoma.
  • Osteosarcoma a primary malignant tumor of bone or soft parts that arises from bone-forming mesenchymal cells, primarily develops in the distal femur, the proximal tibia, the proximal humerus and the distal radius.
  • Classic osteosarcoma demonstrates aggressive, rapid growth with a high risk of local, "skip" metastases and early, pulmonary metastasis. It is the most common bone cancer and the sixth most common cancer in children, and is more frequent in males than females. Most osteosarcomas arise from non-inherited errors in the DNA of growing bone cells. Because these errors occur randomly and unpredictably, there is currently no effective way to prevent this type of cancer [Miller, Dowshen et al.(2002)].
  • ECGC is a potent anticancer agent that has been reported to have a growth inhibitory effect against certain human cancer cell lines [Valcic, Timmerman et. al.
  • the present invention relates to the use of a composition
  • a composition comprising (a) an ascorbic acid compound,
  • composition encompasses liquid and solid preparations of the nutritional compounds referred to above as well as gels thereof.
  • the solid preparations may be manufactured in a suitable form including tablets, capsules, powders, granules, tea preparations or the like. Its well known in the art how to manufacture said liquid, gel-like and solid preparations referred to herein.
  • the composition referred to herein may be provided in accordance with the uses of the invention as mixture of the compounds or by means of a kit including the ingredients separately. The ingredients may be packaged in said kit in separate vials.
  • the composition is also suitable for human or animal use. Preferably, said animal is mammal, most preferably a dog, cat or horse.
  • amino acids "proline” or “lysine” referred to in accordance with the present invention are preferably the L-amino acids.
  • Proline or “Lysine” also encompasses its hydroxyl derivatives hydroxyproline and hydroxylysine as well as salts thereof.
  • ascorbic acid preferably refers to ascorbate, ascorbic acid and salts thereof. Sometimes ascorbate compounds may be referred to as vitamin C.
  • polyphenol compound refers to a preparation of green tea plants comprising the polyphenols compounds that are present in green tea.
  • Polyphenols compounds may be present as up to 30% dry weight in green tea. They include bioflavinoids such as flavanols, flavandiols, flavonoids, and phenolic acids. Flavanols represent the most abundant polyphenols in green tea and are commonly known as catechins. Most preferably, said catechins are EGCG, EG, ECG or EC.
  • EGCG refers to (-)-epigallocatechin-3-gallate
  • EC refers to epicatechin which refers to (-)-epicatechin
  • ECG refers to eipcatechin-3-gallate which refers to (-)-epicatechin-3-gallate
  • EGC refers to epigallocatechin which refers to (-)-epigallocatechin. It is well known in the art how such preparations may be obtained.
  • polyphenols are to be administered in an amount of 200 mg to 5000 mg per day and subject.
  • the composition referred to in accordance with the present invention provides a daily dosage of vitamin C (as ascorbic acid and as Mg, Ca, and palmitate ascorbate) 700 mg; L-lysine 1000 mg; L-proline 750 mg; L-arginine 500 mg; N-acetyl cysteine 200 mg; standardized green tea extract (80% polyphenol) 1000 mg; selenium 30 mg; copper 2 mg; manganese lmg.
  • vitamin C as ascorbic acid and as Mg, Ca, and palmitate ascorbate
  • the pharmaceutical composition to be administered in accordance with the present invention may include a pharmaceutically acceptable carrier, diluent, or excipient.
  • the composition to be used in accordance with the present invention can be prepared by procedures known in the art.
  • Respective ingredients may be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like, xamples of excipients, diluents, and carriers include: i) fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; ii) binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl-pyrrolidone; iii) moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; iv) resorption accelerators such as quaternary ammonium compounds;
  • compositions may also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for example, by intramuscular, subcutaneous or intravenous routes.
  • the formulation is in the form of a pill, tablet, capsule, lozenge, liquid or similar dosage form as referred to aove.
  • the compositions may well be suited to formulation as sustained release dosage forms and the like.
  • treating is used to mean reducing, inhibiting, attenuating or treating the syndromes accompanied with the pathological conditions referred to in accordance with the present invention. Treating becomes apparent for the clinician by monitoring the symptoms accompanied with the said pathological conditions. The symptoms are described in detail in standard text books such as Stedman or Pschyrembel. Treatment preferably refers to significant reduction, inhibition, attenuation or treatment. The significance can be determined by standard methods of statistics, e.g., Student's t-test, chi square test an others.
  • ostosarcoma refers to cancer types of the bone.
  • the symptoms accompanied with said diseases or disorders are well known in the art and described in detail in medical text books such as Stedman or Pschyrembel. Accordingly, the clinician can determine without further ado whether a patient suffers from osteosarcoma.
  • prevention means said the nutritional composition may also be administered in order to avoid the development of osteosarcoma.
  • results of the study underlying the present invention demonstrated significant suppression of osteosarcoma tumor growth in immune impaired (athymic) male nude mice by supplementation with 0.5% of the nutrient mixture (which contains ascorbic acid, lysine, proline, and epigallocatechin gallate). Furthermore nutrient supplementation resulted in decreased mitotic index when contrasted with the control mice, see accompanied Examples.
  • Current treatment of osteosarcoma is associated with poor prognosis, especially due to the increased risk of developing other cancers with chemotherapy. Therefore, new safe effective treatment strategies are needed.
  • NS nutrient mixture
  • mice After injection, the mice were randomly divided into two subgroups; group A was fed a regular diet and group B was fed a regular diet supplemented with 0.5% of the nutrient mixture. Four weeks later, the mice were sacrificed, and their tumors were excised, weighed, and processed for histology. Cell proliferation was evaluated by MTT assay, MMP expression by gelatinase zymography, and invasion through Matrigel. Cells were also treated with phorbol 12- myristate 13 -acetate (PMA) to study enhanced MMP expression. Results showed that the nutrient mixture (NS) inhibited the growth and reduced the size of tumors in nude mice. Furthermore, the mitotic index was decreased in the supplemented group (4-5) in contrast to the control group (12-15).
  • PMA phorbol 12- myristate 13 -acetate
  • osteosarcoma can be treated without harmful side effects of the conventional therapies such as surgery and/or radiation therapy.
  • said ascorbic acid compound is selected from the group consisting of ascorbic acid, a pharmaceutically acceptable ascorbate salt, an ascorbate ester, more preferably ascorbyl palmitate, and/or mixtures of the aforementioned compounds. More preferably, said pharmaceutical acceptable ascorbate salt is selected from the group consisting of calcium ascorbate salts and magnesium ascorbate salts. Suitable amounts of the compounds to be used for the preparation of the composition referred to in accordance with the present invention are disclosed in WO 03/057201 A2, which is hereby incorporated by reference, in detail.
  • the ascorbic acid compound is ascorbic acid in an amount of 25 mg to 5000 mg and/or calcium ascorbate and/or magnesium ascorbate and/or ascorbyl palmitate in the same amounts. All amounts are calculated per day and subject.
  • said L-lysine compound is selected from the group consisting of L-lysine hydrochloride, L-lysine, and pharmaceutically acceptable L-lysine salts.
  • L-lysine compound preferably, may be also a mixture of at least two of the chemicals of the aforementioned group.
  • the L- lysine compound is L-lysine in an amount of 50 mg to 5000 mg per day and subject.
  • said L-proline compound is selected from the group consisting of L- proline hydrochloride, L- proline, and pharmaceutically acceptable L- proline salts.
  • the L-proline compound preferably, may be also a mixture of at least two of the chemicals of the aforementioned group.
  • the L- proline compound is L-proline in an amount of 25 mg to 3000 mg per day and subject.
  • composition further comprises a trace element selected from the group consisting of selenium, manganese, magnesium, calcium, and copper.
  • the composition preferably, comprises at least two, at least three or more of the trace elements of the aforementioned group.
  • the trace elements may be used together, separately or in any comination in the following amounts per day and subject: selenium: 1 ⁇ g to 200 ⁇ g; cooper: 20 ⁇ g to 9000 ⁇ g; manganese: 50 ⁇ g to 10000 ⁇ g; calcium: 300 mg to 600 mg; magnesium: 300 mg to 600 mg.
  • said composition further comprises an L-arginine compound. More preferably, said L-arginine compound is selected from the group consisting of L- arginine hydrochloride, L- arginine, and pharmaceutically acceptable L- arginine salts.
  • Suitable amounts of the compounds to be used for the preparation of the composition referred to in accordance with the present invention are disclosed in WO 03/057201 A2, which is hereby incorporated by reference, in detail.
  • the L-arginine compound preferably, may be also a mixture of at least two of the chemicals of the aforementioned group.
  • the L- arginine compound is L-arginine in an amount of 50 mg to 3000 mg per day and subject.
  • the composition may further comprise N-acetyl cysteine.
  • N-acetyl-cysteine as used herein comprises cysteine or cystine (dimer of cysteine) and cysteine salts thereof. Suitable amounts of the compounds to be used for the preparation of the composition referred to in accordance with the present invention are disclosed in WO 03/057201 A2, which is hereby incorporated by reference, in detail. Preferably, the N-acetyl cystein is administered in an amount of 10 mg to 1500 mg per day and subject.
  • composition is to be administered in oral, parenteral, subcutaneous, intraarterial, or intravenous form.
  • the invention also relates to a method for treating osteosarcoma in a subject comprising the step of administering to a subject suffering from osteosarcoma a composition as defined here- inabove in a therapeutically efficient amount.
  • compositions can be administered to a subject.
  • Particularly preferred techniques are describe in detail in WO 03/057201 A2 which is hereby incorporated by reference.
  • all embodiments of the use of the present invention apply mutatis mutandis for the aforementioned method for treating osteosarcoma.
  • said subject is a human.
  • composition is administered orally, par- entarally, subcutaneously, intraarterially, or intravenously.
  • Figure 1 (A) Effect of NS on total weight of osteosarcoma MNNG xenografts in male nude mice; (B) Histology of tumor tissue in supplemented (Suppl) and contol mice, (C) Photographs of tumors from control and supplemented nude mice.
  • Figure 2 Effect of the nutrient mixture (NS) and PMA on human osteosarcoma cells MNNG-HOS proliferation; (B) Effect of exposure to nutrient composition (NS) on MMP-2 expression by human osteosarcoma MNNG HOS cells.
  • Figure 3 Effect of the nutrient mixture (NS) on Matrigel invasion and migration by human osteosarcoma cells MNNG-HOS.
  • mice Male athymic nude mice (NCr-nu/nu), approximately six weeks of age on arrival, were purchased from Simonsen Laboratories, Gilroy, CA and maintained in microinsulator cages under pathogen-free conditions on a 12-hour light/12-hour dark schedule for a week. All animals were cared for in accordance with institutional guidelines for the care and use of experimental animals. After housing for a week, the mice were inoculated with 3x10 6 human osteosarcoma MNNG-HOS cells in 0.2 ml of PBS and 0.1 ml of Matrigel. After injection, the mice were randomly divided into two groups, A and B. Six mice were allocated to each group.
  • the tumors located in the subcutaneous layer, were expansile, with evidence of peripheral invasion.
  • the neoplasm was composed of spindle shaped or irregularly round cells with large, irregularly round to oval hyperchromatic nuclei and scant cytoplasm with indistinct borders. Irregular areas of tumor necrosis involved about 70% of the tumor mass.
  • Stock solution of the nutrient mixture (total weight 4.4 Gm) for the experiments was composed of the following: vitamin C (as ascorbic acid and as Mg, Ca, and palmitate ascorbate) 700 mg; L-lysine 1000 mg; L-proline 750 mg; L-arginine 500 mg; N-acetyl cysteine 200 mg; standardized green tea extract (80% polyphenol) 1000 mg; selenium 30 mg; copper 2 mg; manganese lmg.
  • vitamin C as ascorbic acid and as Mg, Ca, and palmitate ascorbate
  • Example 2 Effects of the nutrient composition on isolated MNNG-HOS cells from nude mice in culture
  • mice Male athymic nude mice (NCr-nu/nu), approximately six weeks of age on arrival, were purchased from Simonsen Laboratories, Gilroy, CA and maintained in microinsulator cages under pathogen- free conditions on a 12-hour light/12-hour dark schedule for a week. All animals were cared for in accordance with institutional guidelines for the care and use of experimental animals. After housing for a week, the mice were inoculated with 3x10 6 human osteosarcoma MNNG-HOS cells in 0.2 ml of PBS and 0.1 ml of Matrigel. After injection, the mice were randomly divided into two groups, A and B. Six mice were allocated to each group.
  • mice from Group A were fed a regular diet and those in Group B were fed a regular diet supplemented with 0.5% NS.
  • mice were sacrificed, tumors were excised, weighed, fixed in 10% (v/v) buffered formalin and processed for histology- Human osteosarcoma cells were grown in MEM in 24-well tissue culture plates (Costar, Cambridge, MA). Cell cultures were supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml). Cells were incubated with 1 ml of media at 37° C in a tissue culture incubator equilibrated with 95% air and 5% CO 2 .
  • the cells were treated with the nutrient mixture (NS) dissolved in media and tested at 0, 10, 100, 500, and 1000 ⁇ g/ml in triplicate at each dose. A group of cells were also treated with PMA 200 ng/ml. The plates were then returned to the incubator. Cell proliferation was evaluated 24 hrs following incubation with test reagents.
  • NS nutrient mixture
  • MTT assay is a colorimetric assay based on the ability of viable cells to reduce a soluble yellow tetrazolium salt [3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide] (MTT) to a blue formazan crystal by mitochondrial succinate dehydrogenase activity of viable cells.
  • MTT addition 0.5mg/ml
  • the plates were covered and returned to the 37 C incubator for 2 hours, the optimal time for formazan product formation.
  • MMP expression in condition media was determined by gelatinase zymography. Gelatinase zymography was performed in 10% polyacrylamide precast Novex gel (Invitrogen Corporation) in the presence of 0.1% gelatin. Culture media (20 ⁇ l) was loaded and SDS-PAGE was performed with a tris-glycine SDS buffer.
  • the gels were washed with 5% Triton X-100 for 30 minutes. The gels were then incubated for 24 hours at 37 0 C in the presence of 5OmM Tris-HCl, 5mM CaCl 2 , 5 ⁇ M ZnCl 2 , PH 7.5 and stained with Coomassie Blue R 0.5% for 30 minutes and destained. Protein standards were run concurrently and approximate molecular weights were determined.
  • the cells that had penetrated the Matrigel membrane and migrated onto the lower surface of the Matrigel were stained with Hematoxylin and Eosin and visually counted under the microscope.
  • Stock solution of the nutrient mixture was as described above. The results were expressed as means + SD for the groups. Data were analyzed by independent sample "t" test.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of a composition comprising an ascorbic acid compound, a L-lysine compound, a L-proline compound, and a polyphenol compound for the preparation of a pharmaceutical composition for treating osteosarcoma. Moreover, the invention further relates to a method of treatment wherein said composition is administered to a subject suffering from osteosarcoma.

Description

NUTRIENT COMPOSITION COMPRISING GREEN TEA POLYPHENOLS FOR TREATING OSTEOSARCOMA
The present invention relates to the use of a composition comprising an ascorbic acid compound, a L-lysine compound, a L-proline compound, and a polyphenol compound for the preparation of a pharmaceutical composition for treating osteosarcoma. Moreover, the invention further relates to a method of treatment wherein said composition is administered to a subject suffering from osteosarcoma.
Osteosarcoma, a primary malignant tumor of bone or soft parts that arises from bone-forming mesenchymal cells, primarily develops in the distal femur, the proximal tibia, the proximal humerus and the distal radius. Classic osteosarcoma demonstrates aggressive, rapid growth with a high risk of local, "skip" metastases and early, pulmonary metastasis. It is the most common bone cancer and the sixth most common cancer in children, and is more frequent in males than females. Most osteosarcomas arise from non-inherited errors in the DNA of growing bone cells. Because these errors occur randomly and unpredictably, there is currently no effective way to prevent this type of cancer [Miller, Dowshen et al.(2002)].
For decades, standard treatment for osteosarcoma has consisted of surgery (amputation or limb salvage surgery) and chemotherapy, which focus on cancer cell destruction, but do not address metastasis.
Radiation and chemotherapy have not only been ineffective in providing a cure, but also indiscriminately attack all cells - causing cellular damage and destruction of the body's connective tissue, and thus facilitate cancer metastasis. For example, of 31 patients studied with localized osteosarcoma [Jaffe, Carrasco et al. (2002)] and treated with conventional chemo- therapy (high-dose methotrexate and leucovarin rescue in 3 patients and intra-arterial cis- platin in 28 patients) at the Anderson Cancer Center, only 3 patients did not experience local recurrence or pulmonary metastases during the follow-up period of 225+ months. Side effects of chemotherapy include: anemia, abnormal bleeding, increased risk of infection due to destruction of bone marrow, liver and kidney damage, heart problems, and hearing loss. Approximately 20% of children diagnosed with osteosarcoma have an advanced stage of osteosarcoma that has metastasized to the lungs, brain and other bones [Miller, Dowshen et al. (2002)]. Even resection of the primary tumor has been reported to potentiate distant metastasis in osteosarcoma [Tsunemi, Nagoya et al. (2003)].
Several nutrient compounds have been reported to exert anticancer activity. Ascorbic acid has been reported to have cytotoxic and antimetastatic actions on malignant cell lines [Koh, Lee et al. (1998), Roomi, House et al. (1998), Naidu, Karl et al.(2003)]; in addition, low levels of ascorbic acid have been reported in cancer patients [Anthony and Schorah (1982), Nunez, Ortiz de Apodaca et al. (1995), Kurbacher, Wagner et al. (1996)]. ECGC is a potent anticancer agent that has been reported to have a growth inhibitory effect against certain human cancer cell lines [Valcic, Timmerman et. al. (1996), Mukhtar and Ahmed (2000), Yang, Liao et al. (1998)]. The observed effects were, however, rather weak and, thus, not be a suitable basis for a therapeutic approach for a rapid growing and aggressive cancer. Other studies suggested that the synergistic anticancer effect of ascorbic acid and EGCG together with other compounds on several cancer cell lines in tissue culture studies was greater than that of the individual nutrients [Netke, Roomi et al.(2003)].
Clearly, there is a need for safe and effective therapeutic approaches to control the process of cancer metastasis, in particular for aggressive cancers such as osteosarcoma.
The technical problem underlying the present invention, thus, must be seen as the provision of means and methods to comply with the aforementioned needs.
This problem is solved by the embodiments characterized in the claims and herein below.
Accordingly, the present invention relates to the use of a composition comprising (a) an ascorbic acid compound,
(b) a L-lysine compound,
(c) a L-proline compound, and
(d) a polyphenol compound for the preparation of a pharmaceutical composition for treating osteosarcoma. The term "composition" encompasses liquid and solid preparations of the nutritional compounds referred to above as well as gels thereof. The solid preparations may be manufactured in a suitable form including tablets, capsules, powders, granules, tea preparations or the like. Its well known in the art how to manufacture said liquid, gel-like and solid preparations referred to herein. The composition referred to herein may be provided in accordance with the uses of the invention as mixture of the compounds or by means of a kit including the ingredients separately. The ingredients may be packaged in said kit in separate vials. The composition is also suitable for human or animal use. Preferably, said animal is mammal, most preferably a dog, cat or horse.
The amino acids "proline" or "lysine" referred to in accordance with the present invention are preferably the L-amino acids. "Proline" or "Lysine" also encompasses its hydroxyl derivatives hydroxyproline and hydroxylysine as well as salts thereof.
The term "ascorbic acid" preferably refers to ascorbate, ascorbic acid and salts thereof. Sometimes ascorbate compounds may be referred to as vitamin C.
The term "polyphenol compound" as used in accordance with the present invention, preferably, refers to a preparation of green tea plants comprising the polyphenols compounds that are present in green tea. Polyphenols compounds may be present as up to 30% dry weight in green tea. They include bioflavinoids such as flavanols, flavandiols, flavonoids, and phenolic acids. Flavanols represent the most abundant polyphenols in green tea and are commonly known as catechins. Most preferably, said catechins are EGCG, EG, ECG or EC. EGCG refers to (-)-epigallocatechin-3-gallate, EC refers to epicatechin which refers to (-)-epicatechin, ECG refers to eipcatechin-3-gallate which refers to (-)-epicatechin-3-gallate, EGC refers to epigallocatechin which refers to (-)-epigallocatechin. It is well known in the art how such preparations may be obtained. Preferably, polyphenols are to be administered in an amount of 200 mg to 5000 mg per day and subject.
The compounds referred to in accordance with the uses of the present invention may be admixed in any suitable ratios or amounts. Whether such a ratio or amount is suitable can be determined by the skilled person by using the assays specified in the accompanied Examples referred to below. Most preferably, the composition referred to in accordance with the present invention provides a daily dosage of vitamin C (as ascorbic acid and as Mg, Ca, and palmitate ascorbate) 700 mg; L-lysine 1000 mg; L-proline 750 mg; L-arginine 500 mg; N-acetyl cysteine 200 mg; standardized green tea extract (80% polyphenol) 1000 mg; selenium 30 mg; copper 2 mg; manganese lmg.
The pharmaceutical composition to be administered in accordance with the present invention may include a pharmaceutically acceptable carrier, diluent, or excipient. The composition to be used in accordance with the present invention can be prepared by procedures known in the art. Respective ingredients may be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like, xamples of excipients, diluents, and carriers include: i) fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; ii) binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl-pyrrolidone; iii) moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; iv) resorption accelerators such as quaternary ammonium compounds; v) surface active agents such as acetyl alcohol, and glycerol monostearate; v) adsorptive carriers such as kaolin and bentonite; and vi) lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols. The compositions may also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for example, by intramuscular, subcutaneous or intravenous routes. Ideally the formulation is in the form of a pill, tablet, capsule, lozenge, liquid or similar dosage form as referred to aove. The compositions may well be suited to formulation as sustained release dosage forms and the like.
As used herein, the term "treating" is used to mean reducing, inhibiting, attenuating or treating the syndromes accompanied with the pathological conditions referred to in accordance with the present invention. Treating becomes apparent for the clinician by monitoring the symptoms accompanied with the said pathological conditions. The symptoms are described in detail in standard text books such as Stedman or Pschyrembel. Treatment preferably refers to significant reduction, inhibition, attenuation or treatment. The significance can be determined by standard methods of statistics, e.g., Student's t-test, chi square test an others. The term "ostosarcoma" refers to cancer types of the bone. The symptoms accompanied with said diseases or disorders are well known in the art and described in detail in medical text books such as Stedman or Pschyrembel. Accordingly, the clinician can determine without further ado whether a patient suffers from osteosarcoma. The term "prevention" means said the nutritional composition may also be administered in order to avoid the development of osteosarcoma.
The results of the study underlying the present invention, surprisingly, demonstrated significant suppression of osteosarcoma tumor growth in immune impaired (athymic) male nude mice by supplementation with 0.5% of the nutrient mixture (which contains ascorbic acid, lysine, proline, and epigallocatechin gallate). Furthermore nutrient supplementation resulted in decreased mitotic index when contrasted with the control mice, see accompanied Examples. Current treatment of osteosarcoma is associated with poor prognosis, especially due to the increased risk of developing other cancers with chemotherapy. Therefore, new safe effective treatment strategies are needed. In accordance with the present invention the synergistic effect of a nutrient mixture (NS) of lysine, proline, arginine, ascorbic acid, and epigallocatechin gallate on the growth of human osteosarcoma xenografts in athymic nude mice has been investigated. Moreover, the effect of NS on human osteosarcoma cell line MNNG-HOS in vitro was investigated by measuring: cytotoxicity, modulation of MMP-2 and -9, cancer cell invasive potential, and angiogenesis. After one-week of isolation, 5-6 week old athymic male nude mice (n=12) were inoculated with 3xlO6 osteosarcoma cells MNNG-HOS. After injection, the mice were randomly divided into two subgroups; group A was fed a regular diet and group B was fed a regular diet supplemented with 0.5% of the nutrient mixture. Four weeks later, the mice were sacrificed, and their tumors were excised, weighed, and processed for histology. Cell proliferation was evaluated by MTT assay, MMP expression by gelatinase zymography, and invasion through Matrigel. Cells were also treated with phorbol 12- myristate 13 -acetate (PMA) to study enhanced MMP expression. Results showed that the nutrient mixture (NS) inhibited the growth and reduced the size of tumors in nude mice. Furthermore, the mitotic index was decreased in the supplemented group (4-5) in contrast to the control group (12-15). The invasion of osteosarcoma MNNG-HOS cells through Matrigel was significantly reduced in a dose-dependent fashion, with 100% inhibition of invasion of MNNG cells at 50 μg/ml concentration of the nutrient mixture. No significant antiproliferative effect by NS was seen with MNNG cells. Zymography showed dose-dependent inhibition of MMP secretion by MNNG in the presence of NS. Nutrient synergy strongly suppressed the growth of tumors without any adverse effects in nude mice, suggesting the nutrient combination has potential as an anticancer agent. In vitro studies demonstrated inhibition of cancer cell invasion and secretion of MMPs - critical parameters for cancer control and prevention.
Thanks to the present invention osteosarcoma can be treated without harmful side effects of the conventional therapies such as surgery and/or radiation therapy.
The definitions and explanations of the terms made hereinabove apply mutatis mutandis for the other embodiments of the present invention disclosed hereinafter.
In a preferred embodiment of the use of the present invention said ascorbic acid compound is selected from the group consisting of ascorbic acid, a pharmaceutically acceptable ascorbate salt, an ascorbate ester, more preferably ascorbyl palmitate, and/or mixtures of the aforementioned compounds. More preferably, said pharmaceutical acceptable ascorbate salt is selected from the group consisting of calcium ascorbate salts and magnesium ascorbate salts. Suitable amounts of the compounds to be used for the preparation of the composition referred to in accordance with the present invention are disclosed in WO 03/057201 A2, which is hereby incorporated by reference, in detail. Preferably, the ascorbic acid compound is ascorbic acid in an amount of 25 mg to 5000 mg and/or calcium ascorbate and/or magnesium ascorbate and/or ascorbyl palmitate in the same amounts. All amounts are calculated per day and subject.
In a further preferred embodiment of the use of the present invention said L-lysine compound is selected from the group consisting of L-lysine hydrochloride, L-lysine, and pharmaceutically acceptable L-lysine salts.
Suitable amounts of the compounds to be used for the preparation of the composition referred to in accordance with the present invention are disclosed in WO 03/057201 A2, which is hereby incorporated by reference, in detail. The L-lysine compound, preferably, may be also a mixture of at least two of the chemicals of the aforementioned group. Preferably, the L- lysine compound is L-lysine in an amount of 50 mg to 5000 mg per day and subject. In another preferred embodiment of the use of the present invention said L-proline compound is selected from the group consisting of L- proline hydrochloride, L- proline, and pharmaceutically acceptable L- proline salts.
Suitable amounts of the compounds to be used for the preparation of the composition referred to in accordance with the present invention are disclosed in WO 03/057201 A2, which is hereby incorporated by reference, in detail. The L-proline compound, preferably, may be also a mixture of at least two of the chemicals of the aforementioned group. Preferably, the L- proline compound is L-proline in an amount of 25 mg to 3000 mg per day and subject.
In yet another preferred embodiment of the use of the present invention said composition further comprises a trace element selected from the group consisting of selenium, manganese, magnesium, calcium, and copper.
Suitable amounts of the compounds to be used for the preparation of the composition referred to in accordance with the present invention are disclosed in WO 03/057201 A2, which is hereby incorporated by reference, in detail. The composition, preferably, comprises at least two, at least three or more of the trace elements of the aforementioned group. Preferably, the trace elements may be used together, separately or in any comination in the following amounts per day and subject: selenium: 1 μg to 200 μg; cooper: 20 μg to 9000 μg; manganese: 50 μg to 10000 μg; calcium: 300 mg to 600 mg; magnesium: 300 mg to 600 mg.
In a further preferred embodiment of the use of the present invention said composition further comprises an L-arginine compound. More preferably, said L-arginine compound is selected from the group consisting of L- arginine hydrochloride, L- arginine, and pharmaceutically acceptable L- arginine salts.
Suitable amounts of the compounds to be used for the preparation of the composition referred to in accordance with the present invention are disclosed in WO 03/057201 A2, which is hereby incorporated by reference, in detail. The L-arginine compound, preferably, may be also a mixture of at least two of the chemicals of the aforementioned group. Preferably, the L- arginine compound is L-arginine in an amount of 50 mg to 3000 mg per day and subject. In another preferred embodiment of the use of the invention, the composition may further comprise N-acetyl cysteine.
"N-acetyl-cysteine" as used herein comprises cysteine or cystine (dimer of cysteine) and cysteine salts thereof. Suitable amounts of the compounds to be used for the preparation of the composition referred to in accordance with the present invention are disclosed in WO 03/057201 A2, which is hereby incorporated by reference, in detail. Preferably, the N-acetyl cystein is administered in an amount of 10 mg to 1500 mg per day and subject.
In a preferred embodiment of the use of the present invention said composition is to be administered in oral, parenteral, subcutaneous, intraarterial, or intravenous form.
The invention also relates to a method for treating osteosarcoma in a subject comprising the step of administering to a subject suffering from osteosarcoma a composition as defined here- inabove in a therapeutically efficient amount.
It is well known for the person skilled in the art how such compositions can be administered to a subject. Particularly preferred techniques are describe in detail in WO 03/057201 A2 which is hereby incorporated by reference. Moreover, all embodiments of the use of the present invention apply mutatis mutandis for the aforementioned method for treating osteosarcoma.
In a preferred embodiment of the method said subject is a human.
In a further preferred embodiment of the method the composition is administered orally, par- entarally, subcutaneously, intraarterially, or intravenously.
Full bibliographic information on the references cited above and below will be found below. The disclosure content of these references is hereby incorporated by reference. References
1. H.M. Anthony, CJ. Schorah (1982). Severe hypovitaminosis C in lung-cancer patients: The utilization of vitamin C in surgical repair and lymphocyte related host resistance. Br J Cancer. 46: 354-367
2. N. Jaffe, H. Carrasco, K. Raymond, A. Ayala, F. Eftekhari (2002). Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer. 10: 2202-10.
3. W.S. Koh, S. J. Lee, H. Lee, C. Park, M.H. Park, W.S. Kim, S.S. Yoon, K. Park, S.I. Hong, M.H. Chung, CH. Park (1998). Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 8: 2487-2493.
4. CM. Kurbacher, U. Wagner, B. Kolster, P.E. Andreotti, D. Krebs, H. W. Bruckner (1996). Ascorbic acid (vitamin C) improves the antineoplastic activity doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 103(2): 183-189.
5. J.T. Masman (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay. J Immunol Methods 65: 55-57
6. R. Miller, S. Dowshen, and M. Trigg, Childhood Cancer: Osteosarcoma (May 2002) The Nemours Foundation: Kids Health http://kidshealth.org/parent/medical/cancer/cancer osteosarcoma p 1 -3.html
7. H. Mukhtar and N. Ahmed (2000). Tea polypheonols: prevention of cancer and optimizing health. Am JCUn Nutr. 71: 1698S-1720S.
8. K.A. Naidu, R.C Karl, K.A. Naidu, D. Coppola D (2003). Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor. Dig Dis Sci. 48(1): 230-7.
9. S.P. Netke, M. W. Roomi, V. Ivanov, A. Niedzwiecki, and M. Rath. A specific combination of ascorbic acid, lysine, proline and epigallocatechin gallate inhibits prolif- eration and extracellular matrix invasion of various human cancer cell lines. Research Communications in Pharmacology and Toxicology: Emerging Drugs. 2, 37-50.
10. C. Nunez, Y. Ortiz de Apodaca, A. Ruiz (1995). Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr HospΛO: 68-372.
11. M. Rath and L. Pauling (1992). Plasmin-induced proteolysis and the role of apoprotein^), lysine and synthetic analogs. Or thomolecular Medicine.7:17-23.
12. M. W. Roomi, D. House, M. Eckert-Maksic, Z.B. Maksic, CS. Tsao (1998). Growth suppression of malignant leukemia cell line in vitro by ascorbic acid (vitamin C) and its derivatives. Cancer Letters 122: 93-99.
13. T. Tsunemi, S. Nagoya, M. Kaya, S. Kawaguchi, T. Wada, T. Yamashita, S. Ishii (2003) Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Or- thop. 407:159-66.
14. S. Valcic, B.N. Timmerman, D.S. Alberts, G.A. Wachter, M. Krutzch, J. Wymer, J.M. Guillen (1996). Inhibitory effects of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs. 7: 461-468.
15. G.Y. Yang, J. Liao, K. Kim, E.J. Yurkow, CS. Yang (1998). Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis. 19:611-616.
The figure show:
Figure 1: (A) Effect of NS on total weight of osteosarcoma MNNG xenografts in male nude mice; (B) Histology of tumor tissue in supplemented (Suppl) and contol mice, (C) Photographs of tumors from control and supplemented nude mice.
Figure 2: (A) Effect of the nutrient mixture (NS) and PMA on human osteosarcoma cells MNNG-HOS proliferation; (B) Effect of exposure to nutrient composition (NS) on MMP-2 expression by human osteosarcoma MNNG HOS cells.
Figure 3: Effect of the nutrient mixture (NS) on Matrigel invasion and migration by human osteosarcoma cells MNNG-HOS.
The invention will be illustrated by the following Examples. However, the Examples shall not be used to limit the scope of the invention.
Example 1: Treatment of osteosarcoma in nude mice
Human osteosarcoma cells MNNG-HOS obtained from ATCC (American Type Culture Collection, Rockville, MD) were maintained in MEM culture, supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin. The media and sera used were obtained from ATCC, and antibiotics (penicillin and streptomycin) were from Gibco BRL, Long Island, NY. At near confluence, the cultured cells were detached by trypsinizing, washed with PBS, and diluted and emulsified to a concentration of 3xlO6 cells in 0.2 ml PBS and 0.1 ml Matrigel (BD Bioscience, Bedford, MA) for inoculation. Male athymic nude mice (NCr-nu/nu), approximately six weeks of age on arrival, were purchased from Simonsen Laboratories, Gilroy, CA and maintained in microinsulator cages under pathogen-free conditions on a 12-hour light/12-hour dark schedule for a week. All animals were cared for in accordance with institutional guidelines for the care and use of experimental animals. After housing for a week, the mice were inoculated with 3x106 human osteosarcoma MNNG-HOS cells in 0.2 ml of PBS and 0.1 ml of Matrigel. After injection, the mice were randomly divided into two groups, A and B. Six mice were allocated to each group. From day one, mice from Group A were fed a regular diet and those in Group B were fed a regular diet supplemented with 0.5% NS. After four weeks, mice were sacrificed, tumors were excised, weighed, fixed in 10% (v/v) buffered formalin and processed for histology. Results showed that the nutrient supplemented nude mice developed significantly smaller tumors (by 53%, p = 0.0001) and less vascular ones than did the control group of nude mice (Figure IA). Furthermore, histological examination revealed that mitotic figures in the control group averaged 12-15 per high power field; in contrast, the nutrient supplemented rats developed tumors with a decreased mitotic figure (4-5 per high-power field) (Figure IB). The tumors, located in the subcutaneous layer, were expansile, with evidence of peripheral invasion. The neoplasm was composed of spindle shaped or irregularly round cells with large, irregularly round to oval hyperchromatic nuclei and scant cytoplasm with indistinct borders. Irregular areas of tumor necrosis involved about 70% of the tumor mass.
Stock solution of the nutrient mixture (total weight 4.4 Gm) for the experiments was composed of the following: vitamin C (as ascorbic acid and as Mg, Ca, and palmitate ascorbate) 700 mg; L-lysine 1000 mg; L-proline 750 mg; L-arginine 500 mg; N-acetyl cysteine 200 mg; standardized green tea extract (80% polyphenol) 1000 mg; selenium 30 mg; copper 2 mg; manganese lmg.
The results were expressed as means + SD for the groups. Data were analyzed by independent sample "t" test.
Example 2: Effects of the nutrient composition on isolated MNNG-HOS cells from nude mice in culture
Human osteosarcoma cells MNNG-HOS obtained from ATCC (American Type Culture Collection, Rockville, MD) were maintained in MEM culture, supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin. The media and sera used were obtained from ATCC, and antibiotics (penicillin and streptomycin) were from Gibco BRL, Long Island, NY. At near confluence, the cultured cells were detached by trypsinizing, washed with PBS, and diluted and emulsified to a concentration of 3x106 cells in 0.2 ml PBS and 0.1 ml Matrigel (BD Bioscience, Bedford, MA) for inoculation.
Male athymic nude mice (NCr-nu/nu), approximately six weeks of age on arrival, were purchased from Simonsen Laboratories, Gilroy, CA and maintained in microinsulator cages under pathogen- free conditions on a 12-hour light/12-hour dark schedule for a week. All animals were cared for in accordance with institutional guidelines for the care and use of experimental animals. After housing for a week, the mice were inoculated with 3x106 human osteosarcoma MNNG-HOS cells in 0.2 ml of PBS and 0.1 ml of Matrigel. After injection, the mice were randomly divided into two groups, A and B. Six mice were allocated to each group. From day one, mice from Group A were fed a regular diet and those in Group B were fed a regular diet supplemented with 0.5% NS. After four weeks, mice were sacrificed, tumors were excised, weighed, fixed in 10% (v/v) buffered formalin and processed for histology- Human osteosarcoma cells were grown in MEM in 24-well tissue culture plates (Costar, Cambridge, MA). Cell cultures were supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml). Cells were incubated with 1 ml of media at 37° C in a tissue culture incubator equilibrated with 95% air and 5% CO2. At near confluence, the cells were treated with the nutrient mixture (NS) dissolved in media and tested at 0, 10, 100, 500, and 1000 μg/ml in triplicate at each dose. A group of cells were also treated with PMA 200 ng/ml. The plates were then returned to the incubator. Cell proliferation was evaluated 24 hrs following incubation with test reagents.
Cell proliferation was evaluated based on the MTT assay. The MTT assay [Masman JT, (1983)] is a colorimetric assay based on the ability of viable cells to reduce a soluble yellow tetrazolium salt [3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide] (MTT) to a blue formazan crystal by mitochondrial succinate dehydrogenase activity of viable cells. After MTT addition (0.5mg/ml) the plates were covered and returned to the 37 C incubator for 2 hours, the optimal time for formazan product formation. Following incubation, the supernatant was carefully removed from the wells, the formazan product was dissolved in 1 ml DMSO, and absorbance was measured at 570 nm in Bio Spec 1601, Shimadzu spectrometer. The OD57O of the DMSO solution in each well was considered to be proportional to the number of cells. The OD57O of the control (treatment without supplement) was considered 100%. MMP expression in condition media was determined by gelatinase zymography. Gelatinase zymography was performed in 10% polyacrylamide precast Novex gel (Invitrogen Corporation) in the presence of 0.1% gelatin. Culture media (20μl) was loaded and SDS-PAGE was performed with a tris-glycine SDS buffer. After electrophoresis, the gels were washed with 5% Triton X-100 for 30 minutes. The gels were then incubated for 24 hours at 370C in the presence of 5OmM Tris-HCl, 5mM CaCl2, 5μM ZnCl2, PH 7.5 and stained with Coomassie Blue R 0.5% for 30 minutes and destained. Protein standards were run concurrently and approximate molecular weights were determined.
Invasion studies were conducted using Matrigel™ (Becton Dickinson) inserts in 24-well plates. Suspended in medium, osteosarcoma cells were supplemented with nutrients, as specified in the design of the experiment and seeded on the insert in the well. Thus both the medium on the insert and in the well contained the same supplements. The plates with the inserts were then incubated in a culture incubator equilibrated with 95% air and 5% CO2 for 24 hours. After incubation, the media from the wells were withdrawn. The cells on the upper surface of the inserts were gently scrubbed away with cotton swabs. The cells that had penetrated the Matrigel membrane and migrated onto the lower surface of the Matrigel were stained with Hematoxylin and Eosin and visually counted under the microscope. Stock solution of the nutrient mixture was as described above. The results were expressed as means + SD for the groups. Data were analyzed by independent sample "t" test.

Claims

Claims
1. Use of a composition comprising
(a) an ascorbic acid compound,
(b) a L-lysine compound,
(c) a L-proline compound, and
(d) a polyphenol compound for the preparation of a pharmaceutical composition for treating osteosarcoma.
2. The use of claim 1, wherein said ascorbic acid compound is selected from the group consisting of ascorbic acid, a pharmaceutically acceptable ascorbate salt, an ascorbate ester and/or mixtures of the aforementioned compounds.
3. The use of claim 2, wherein said pharmaceutical acceptable ascorbate salt is selected from the group consisting of calcium ascorbate salts and magnesium ascorbate salts.
4. The use of claim 1, wherein said ascorbate compound is an ascorbate ester.
5. The use of claim 4, wherein said ascorbate ester is ascorbyl palmitate.
6. The use of any one of claims 1 to 5, wherein said L-lysine compound is selected from the group consisting of L-lysine hydrochloride, L-lysine, and pharmaceutically acceptable L-lysine salts.
7. The use of any one of claims 1 to 6, wherein said L-proline compound is selected from the group consisting of L- proline hydrochloride, L- proline, and pharmaceutically acceptable L- proline salts.
8. The use of any one of claims 1 to 7, wherein said composition further comprises a trace element selected from the group consisting of selenium, manganese, magnesium, calcium, and copper.
9. The use of any one of claims 1 to 8, wherein said composition further comprises an L- arginine compound.
10. The use of claim 9, wherein said L-arginine compound is selected from the group consisting of L- arginine hydrochloride, L- arginine, and pharmaceutically acceptable L- arginine salts.
11. The use of any one of claims 1 to 10, wherein said composition further comprises N- acetyl cysteine.
12. The use of any one of claims 1 to 11, wherein said composition is to be administered in oral, parenteral, subcutaneous, intraarterial, or intravenous form.
13. A method for treating osteosarcoma in a subject comprising the step of administering to a subject suffering from osteosarcoma a composition as defined in any one of claims 1 to 12 in a therapeutically efficient amount.
14. The method of claim 13, wherein said subject is a human.
15. The method of claim 13 or 14, wherein the composition is administered orally, paren- tarally, subcutaneously, intraarterial Iy, or intravenously.
EP05738146A 2005-04-11 2005-04-11 Nutrient composition comprising green tea polyphenols for treating osteosarcoma Withdrawn EP1874354A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/003775 WO2006108430A1 (en) 2005-04-11 2005-04-11 Nutrient composition comprising green tea polyphenols for treating osteosarcoma

Publications (1)

Publication Number Publication Date
EP1874354A1 true EP1874354A1 (en) 2008-01-09

Family

ID=35295399

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05738146A Withdrawn EP1874354A1 (en) 2005-04-11 2005-04-11 Nutrient composition comprising green tea polyphenols for treating osteosarcoma

Country Status (3)

Country Link
EP (1) EP1874354A1 (en)
BR (1) BRPI0520221A2 (en)
WO (1) WO2006108430A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102449799B (en) 2009-06-01 2016-09-28 日立化成工业株式会社 Organic electronic material and containing the ink composite of this organic electronic material and use organic film, organic electronic element, organic electroluminescent device, illuminator and the display device that they form
JP2016519092A (en) * 2013-03-18 2016-06-30 デンタルメッド ファーム ホールディング リミテッド Combinations of N-acetylcysteine derivatives and cranberry polyphenols in compositions and methods for preventing and treating periodontal disease and peri-implantitis
WO2022124386A1 (en) * 2020-12-07 2022-06-16 L' Oreal Composition comprising ascorbic acid and cyclic amino acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198465A (en) * 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
WO2000057875A1 (en) * 1999-03-30 2000-10-05 Purdue Research Foundation Compositions containing tea catechins as cancer specific proliferation inhibitors
ES2261136T3 (en) * 2000-10-09 2006-11-16 Matthias Dr. Med. Rath THERAPEUTIC COMPOSITION OF ASCORBATE WITH LISINE AND ARGININE FOR THE PREVENTION AND TREATMENT OF CANCER.
YU75003A (en) 2002-01-11 2006-08-17 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006108430A1 *

Also Published As

Publication number Publication date
WO2006108430A8 (en) 2007-01-25
WO2006108430A1 (en) 2006-10-19
BRPI0520221A2 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
AU2003235762B2 (en) A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
RU2435580C2 (en) Compositions possessing anti-cancirogenic properties
ES2341717T3 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES, AMONG OTHERS, VITAMIN C, MAGNESIUM AND EXTRACT OF GREEN TO DELAY CARDIOVASCULAR DISEASES (SMC PROLIFERATION).
KR20060063797A (en) Pharmaceutical composition and method for alleviating side-effects of estrogen replacement therapy
Roomi et al. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES. 1.
WO2006108430A1 (en) Nutrient composition comprising green tea polyphenols for treating osteosarcoma
US7166309B2 (en) Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
EP1689381B1 (en) Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases (smc proliferation)
WO2006108429A1 (en) Nutrient composition for treating sarcoma and prostate cancer
KR20080016547A (en) Nutrient composition comprising green tea polyphenols for treating osteosarcoma
Roomi et al. In vivo and in vitro antitumor effect of nutrient synergy on human osteosarcoma cell line MNNG-HOS
KR20080016548A (en) Nutrient compositon for treating sarcoma and prostate cancer
CN101180049A (en) Nutritive composition for treating sarcoma and prostate cancer
WO2004105679A2 (en) Use of a nutritional composition for treating hypertension
RU2328282C1 (en) Pharmaceutical formulation for metastasis prevention and increasing of tumour sensitisation to chemotherapeutic agents
CN101180080A (en) Nutritive composition including green tea polyphenol for treating osteosarcoma
CA2524381A1 (en) Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
Room et al. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES. 1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17Q First examination report despatched

Effective date: 20080205

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NIEDZWIECKI, ALEKSANDRA

Inventor name: KALINOVSKY, TATIANA

Inventor name: IVANOV, VADIM

Inventor name: ROOMI, M., WAHEED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NIEDZWIECKI, ALEKSANDRA

Inventor name: KALINOVSKY, TATIANA

Inventor name: IVANOV, VADIM

Inventor name: ROOMI, M., WAHEED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20081222